An Exploratory Clinical Study to Evaluate the Skin Tolerability, Drug Delivery and Safety of Multiple Formulations of Once-Weekly Investigational Transdermal Delivery System in Healthy Volunteers

INC Research Australia Pty Ltd0 sites24 target enrollmentApril 11, 2019

Overview

No summary available.

Registry

who.int

Start Date

April 11, 2019

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Healthy, adult, Caucasian females and males aged 50 to 85 years (inclusive) on the day of randomization. Enrollment will aim for 100 percent females; however, up to 25 percent males may be enrolled per the Sponsor’s approval and a minimum of 5 subjects (3\-4 females, and 1\-2 males if applicable) who are between the ages of 70 and 85 years.
•2\. Has a body mass index (BMI) between 18\-32 kg/m^2 (inclusive).
•3\. Have a Fitzpatrick skin type of I, II, or III
•4\. Must be willing and able to understand and comply with the scheduled study visits, treatment plans, laboratory tests, and other procedures by providing a signed and dated written informed consent prior to the initiation of any study procedures.
•5\. Women of child\-bearing potential and men should be sexually inactive (abstinent). Abstinence, defined as complete avoidance of heterosexual intercourse, is an acceptable form of contraception. .
•6\. Willing and able to discontinue all nonsteroidal anti\-inflammatory drugs (NSAIDs) or cyclooxygenase\-2 (COX\-2\) NSAID analgesic therapy, 30 days prior to Day 1 and until completion of the Study Exit Visit.
•7\. If the subject is receiving allowed medications for the treatment of non\-excluded medical conditions, the dose must be stable for at least 28 days before randomization on Day 1\.

•1\. Participation in another clinical study with an IP or device within 30 days or 5 half\-lives, whichever is longer, prior to screening.
•2\. Plasma donation within 28 days of screening or any blood donation or blood loss greater than 500 mL within 3 months of screening.
•3\. Has skin color that may not allow reliable evaluation of irritation.
•4\. Female subjects with a positive pregnancy test or lactating.
•5\. Has intolerance to venipuncture and/or inability to comply with the blood sampling required for this study.
•6\. Has cuts, scratches/abrasions, scars, breaks in the skin surface, skin with excessive hair, indications of sunburn, excessive skin tanning, stretch marks at the application site, recent tattoos (within the last 6 months) or has any abnormalities at the intended application sites which would affect absorption of the IP.
•7\. Unwilling to refrain from using tanning salons, saunas, or from sunbathing during the course of the study. Unwilling to avoid shaving of the application site, waxing of the application site, or using lotion hair remover on or near application site from 48 hours before patch application and during the conduct of the study.
•8\. Has a history of or is currently consuming high caffeine levels
•9\. Smokes more than 20 cigarettes per day for more than 10 years
•10\. Presence of any major psychiatric disorder